Helen Tesfaye - Concepedia

Author

Helen Tesfaye

Brigham and Women's Hospital ORCID

Also Known As

H Tesfaye, H Tufa Tesfaye, H. Tesfaye, HELEN TESFAYE, Helen Tesfaye, Hiwot Tesfaye, Sushama Kattinakere Sreedhara

Publications

681

Citations

H-Index

Concepts

All Affiliations

Brigham and Women's Hospital Harvard University Massachusetts General Hospital Boehringer Ingelheim (Germany)Jewish General Hospital

About

Helen Tesfaye is an author at Brigham and Women's Hospital.

Helen Tesfaye

Publications

293

Citations

H-Index

Page 1

	Year	Citations
Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020 Geetha Iyer, Helen Tesfaye, Nazleen F. Khan, JAMA Network Open	2023	44
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes Julie M. Paik, Helen Tesfaye, Gary C. Curhan, JAMA Internal Medicine	2024	42
Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity Kueiyu Joshua Lin, Sebastian Schneeweiß, Helen Tesfaye, Drugs	2020	37
Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism Ajinkya Pawar, Joshua J. Gagne, Chandrasekar Gopalakrishnan, JAMA	2022	31
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiß, JAMA Network Open	2022	31
Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study Devin Abrahami, Helen Tesfaye, Hui Yin, Diabetes Care	2022	28
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study Richeek Pradhan, Elisabetta Patorno, Helen Tesfaye, American Journal of Epidemiology	2022	23
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiß, Cardiovascular Diabetology	2024	21
Effectiveness and safety of empagliflozin: final results from the EMPRISE study Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiß, Diabetologia	2024	14
Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA Julie C. Lauffenburger, Helen Tesfaye, Daniel H. Solomon, BMJ Open	2023	11

Page 1